Omada Health (NASDAQ:OMDA) CEO Sean Duffy Sells 12,944 Shares of Company Stock

Omada Health, Inc. (NASDAQ:OMDA) CEO Sean Duffy sold 12,944 shares of Omada Health stock in a transaction that occurred on Wednesday, November 4th. The stock was sold at an average price of $19.22, for a total value of $248,783.68. Following the completion of the transaction, the chief executive officer directly owned 382,594 shares in the company, valued at approximately $7,353,456.68. This represents a 3.27% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Omada Health Stock Down 20.4%

Shares of OMDA stock traded down $3.86 during trading hours on Friday, reaching $15.09. 4,709,304 shares of the company’s stock were exchanged, compared to its average volume of 1,032,454. Omada Health, Inc. has a fifty-two week low of $10.28 and a fifty-two week high of $25.45. The stock has a market capitalization of $923.81 million, a P/E ratio of 71.86 and a beta of 2.13. The business has a fifty day moving average price of $20.14 and a 200-day moving average price of $17.74.

Omada Health (NASDAQ:OMDA) last announced its earnings results on Thursday, November 5th. The company reported $0.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.02 by $0.08. Omada Health had a net margin of 1.39% and a return on equity of 2.60%. The business had revenue of $91.31 million for the quarter. As a group, research analysts expect that Omada Health, Inc. will post 0.09 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have issued reports on OMDA. BTIG Research reiterated a “buy” rating and set a $35.00 price objective on shares of Omada Health in a research note on Friday, September 11th. Canaccord Genuity Group boosted their target price on shares of Omada Health from $24.00 to $28.00 and gave the company a “buy” rating in a research note on Tuesday, July 21st. JPMorgan Chase & Co. upped their target price on shares of Omada Health from $26.00 to $30.00 and gave the stock an “overweight” rating in a report on Friday, August 14th. Citigroup reiterated an “outperform” rating on shares of Omada Health in a research report on Friday, August 14th. Finally, Citizens Jmp lifted their price target on shares of Omada Health from $27.00 to $32.00 and gave the company a “market outperform” rating in a report on Friday, August 14th. Eleven analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $26.33.

Institutional Investors Weigh In On Omada Health

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Sterling Capital Management LLC lifted its position in shares of Omada Health by 1,161.6% during the third quarter. Sterling Capital Management LLC now owns 1,577 shares of the company’s stock worth $33,000 after purchasing an additional 1,452 shares in the last quarter. Integrated Wealth Concepts LLC acquired a new position in Omada Health during the 2nd quarter worth $53,000. State of Alaska Department of Revenue acquired a new position in Omada Health during the 3rd quarter worth $59,000. Versant Capital Management Inc boosted its position in Omada Health by 319.3% in the 2nd quarter. Versant Capital Management Inc now owns 2,998 shares of the company’s stock valued at $66,000 after buying an additional 2,283 shares during the last quarter. Finally, Legal & General Group Plc acquired a new stake in shares of Omada Health in the 2nd quarter valued at $76,000.

Omada Health News Roundup

Here are the key news stories impacting Omada Health this week:

• Positive Sentiment: Omada reported Q3 revenue of $91 million, up 34% year over year, and total members grew 36% to a record 1.1 million. Net income was $7 million versus a year-ago loss, while adjusted EBITDA increased to $12 million. The company also raised its full-year 2026 financial outlook. Omada Health Reports Third Quarter 2026 Results
• Positive Sentiment: Quarterly revenue exceeded FactSet’s estimate, and reported earnings also topped consensus estimates, providing evidence of stronger-than-expected operating performance. Earnings Flash: Q3 Revenue
• Neutral Sentiment: Unusual options activity was reported after Omada’s earnings, signaling heightened trading interest but not indicating a clear direction for the stock. Unusual Options Volume Report
• Negative Sentiment: Several analysts took a more cautious stance: Wells Fargo cut its price target to $19 and maintained an “equal weight” rating, while Zacks Research downgraded OMDA from “strong buy” to “hold.” Wells Fargo analyst actions Zacks Research analyst action
• Negative Sentiment: Barclays also lowered its target from $24 to $22, although it retained an “overweight” rating. Barclays analyst action

Omada Health Company Profile

Omada Health, Inc (NASDAQ: OMDA) is a digital health company that provides virtual care programs for people managing chronic conditions. Its platform combines personalized health coaching, clinical support, behavioral-change tools and connected devices to help members monitor and improve their health.

The company’s offerings focus primarily on cardiometabolic conditions, including diabetes, prediabetes, hypertension and obesity, as well as musculoskeletal conditions. Depending on the program, members may receive access to digital lessons, health tracking, remote monitoring, care teams and clinical guidance through Omada’s technology platform.

Omada Health was founded in 2011 and serves employers, health plans and other healthcare organizations in the United States.